Lung cancer (LC) continues to pose a significant global medical burden, necessitating a
comprehensive understanding of its molecular foundations to establish effective treatment …

Lung cancer (LC) is a heterogeneous disease with high malignant degree, rapid growth,
and early metastasis. The clinical outcomes of LC patients are generally poor due to the …

Despite recent advancements in cancer immunotherapy, challenges have yet to be
surmounted to achieve two major goals of magnifying antitumor immunity and remodeling …

Lung cancer accounts for a relatively high proportion of malignant tumors. As the most
prevalent type of lung cancer, non-small cell lung cancer (NSCLC) is characterized by high …

Recent advances in neoantigen research have accelerated the development of tumor
immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody …

Malignant expansion and rapid metastasis are the main limiting factors to successful
treatment of lung cancer. Messenger RNA (mRNA) tumor vaccines are a promising …

Nowadays, lung cancer is the most common cause of cancer-related deaths in both men
and women globally. Despite the development of extremely efficient targeted agents, lung …

This paper addresses the dynamics of lung cancer by employing a fractional-order
mathematical model that investigates the combined therapy of surgery and immunotherapy …

Cancer receives enduring international attention due to its extremely high morbidity and
mortality. Immunotherapy, which is generally expected to overcome the limits of traditional …

Multidrug resistance (MDR) poses a significant obstacle to effective cancer treatment, and
the tumor microenvironment (TME) is crucial for MDR development and reversal. The TME …